Summary
Global Markets Direct’s, ‘Acute Heart Failure - Pipeline Review, H1 2016’, provides an overview of the Acute Heart Failure pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report reviews pipeline therapeutics for Acute Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Heart Failure therapeutics and enlists all their major and minor projects
- The report assesses Acute Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Heart Failure
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Amgen Inc.
Angion Biomedica Corp.
Capricor Therapeutics, Inc.
Lee's Pharmaceutical Holdings Limited
Novartis AG
Nyken B.V.
Ono Pharmaceutical Co., Ltd.
PhaseBio Pharmaceuticals, Inc.
Trevena, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Acute Heart Failure Overview 7
Therapeutics Development 8
Pipeline Products for Acute Heart Failure - Overview 8
Acute Heart Failure - Therapeutics under Development by Companies 9
Acute Heart Failure - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Acute Heart Failure - Products under Development by Companies 13
Acute Heart Failure - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
Angion Biomedica Corp. 15
Capricor Therapeutics, Inc. 16
Lee's Pharmaceutical Holdings Limited 17
Novartis AG 18
Nyken B.V. 19
Ono Pharmaceutical Co., Ltd. 20
PhaseBio Pharmaceuticals, Inc. 21
Trevena, Inc. 22
Acute Heart Failure - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ANG-4011 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
cenderitide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
istaroxime - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NYK-1112 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
omecamtiv mecarbil MR - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ONO-4232 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PB-1046 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
serelaxin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TRV-027 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TRV-120023 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ularitide - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Acute Heart Failure - Recent Pipeline Updates 51
Acute Heart Failure - Dormant Projects 65
Acute Heart Failure - Discontinued Products 66
Acute Heart Failure - Product Development Milestones 67
Featured News & Press Releases 67
Dec 11, 2015: Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure 67
Dec 03, 2015: Trevena Granted Key Composition of Matter and Use Patent for TRV027 in Europe 67
May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure 68
Mar 09, 2015: Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure 68
Feb 03, 2015: TRV027 Phase 2b BLAST-AHF Trial Design Published in Journal of the American College of Cardiology: Heart Failure 69
Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide 70
Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation 70
Aug 05, 2014: Trevena Granted Key U.S. Method of Use Patent for TRV027 71
May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure 71
May 19, 2014: Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74
List of Tables
Number of Products under Development for Acute Heart Failure, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Acute Heart Failure - Pipeline by Amgen Inc., H1 2016 14
Acute Heart Failure - Pipeline by Angion Biomedica Corp., H1 2016 15
Acute Heart Failure - Pipeline by Capricor Therapeutics, Inc., H1 2016 16
Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 17
Acute Heart Failure - Pipeline by Novartis AG, H1 2016 18
Acute Heart Failure - Pipeline by Nyken B.V., H1 2016 19
Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 20
Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 21
Acute Heart Failure - Pipeline by Trevena, Inc., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Acute Heart Failure Therapeutics - Recent Pipeline Updates, H1 2016 51
Acute Heart Failure - Dormant Projects, H1 2016 65
Acute Heart Failure - Discontinued Products, H1 2016 66
List of Figures
Number of Products under Development for Acute Heart Failure, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Top 10 Targets, H1 2016 24
Number of Products by Stage and Top 10 Targets, H1 2016 24
Number of Products by Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Routes of Administration, H1 2016 28
Number of Products by Stage and Routes of Administration, H1 2016 28
Number of Products by Molecule Types, H1 2016 30
Number of Products by Stage and Molecule Types, H1 2016 30
